Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options.
Simonsson
B
B
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000276:immunology; D006801:Humans; D006912:Hydroxyquinolines / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D017708:Leukocyte Transfusion; D018365:Neoplasm, Residual
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D006912:Hydroxyquinolines; D007376:Interleukin-2; C045282:roquinimex